Actualités sur Medicale

22.06.2017 – 07:01
Shire Pharmaceuticals Group Plc
Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease
Zug, Switzerland (ots/PRNewswire) - VEYVONDI is the first and only recombinant von Willebrand factor treatment for adults with von Willebrand disease, the most common inherited bleeding disorder[1],[2],[3] Shire plc (LSE: SHP, NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare ...
plus
20.06.2017 – 17:00
Debiopharm International SA
Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor
Craigavon, N.I., UK, Lausanne, Switzerland (ots) - Almac Discovery (www.almacgroup.com/discovery), a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Debiopharm International SA (Debiopharm - www.debiopharm.com), a Switzerland based specialty ...
plus
20.06.2017 – 13:31
Accuray Europe
IUCT Oncopole Advances Cancer Care in France with the New Accuray Radixact(TM) System
Sunnyvale, California (ots/PRNewswire) - The French Cancer Institute is Building its Re-irradiation and Adaptive Radiotherapy Program Using the Latest Technology Developed by Accuray Accuray Incorporated (NASDAQ: ARAY) announced today that the University Cancer Institute of Toulouse Oncopole (IUCT Oncopole) is providing advanced radiation treatments to cancer patients ...
plus
20.06.2017 – 11:02
ALK
ALK Symposium Reveals Early Treatment is Critical for Respiratory Allergic Disease in Children and Adolescents
Hørsholm, Denmark (ots/PRNewswire) - - Allergic rhinitis has a major impact on children's quality of life - Children with allergic rhinitis have an increased risk of developing asthma - Early treatment may prevent asthma symptoms In a symposium sponsored by ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF), leading ...
plus
20.06.2017 – 09:14
kENUP Foundation
European Investment Bank (EIB) supports Development and Production of Universal Flu Vaccine Candidate
Luxembourg, and Ness Ziona, Israel (ots) - - Cross reference: Picture is available at http://www.presseportal.de/pm/127019/3664051 - The European Investment Bank (EIB) and BiondVax Pharmaceuticals Ltd., developer of the Universal Flu Vaccine candidate M-001, announced that they have entered into a EUR20 million loan ...
plus
15.06.2017 – 14:00
Debiopharm International SA
Debiopharm International SA Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN
Lausanne (ots) - A total of 96 patients randomized in France and Switzerland. Results expected in Q1 2019. Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the completion of enrollment in dose finding and ...
plus
15.06.2017 – 07:01
LEO Pharma
LEO Pharma Starts Phase 3 Clinical Study for Tralokinumab in Atopic Dermatitis
Ballerup, Denmark (ots/PRNewswire) - LEO Pharma today announced that the first patients have been dosed in a phase 3 clinical study of tralokinumab. Tralokinumab is an investigational human monoclonal antibody that specifically targets the cytokine IL-13[1], which plays an important role in the development of moderate-to-severe atopic dermatitis[2]. Tralokinumab is not ...
plus
14.06.2017 – 17:26
Janssen EMEA
Janssen Presents Long Term Phase 3 Efficacy and Safety Data of Sirukumab in Rheumatoid Arthritis Patients Who had an Inadequate Response and/or Who Were Intolerant to Anti-TNFs
Madrid (ots/PRNewswire) - Sirukumab Phase 3 Data Presented at the Annual European Congress of Rheumatology (EULAR) 2017 also Show Significant Improvement in Quality of Life Measures Janssen-Cilag International NV (Janssen) today announced long-term results from SIRROUND-T*, a pivotal Phase 3 study that showed ...
plus
13.06.2017 – 03:31
Novo Nordisk
New LEADER Analysis Shows Victoza® Reduces Cardiovascular Risk in People With Type 2 Diabetes Regardless of Severe Hypoglycaemia Events
Bagsværd, Denmark (ots/PRNewswire) - Findings from a post hoc analysis of the LEADER cardiovascular (CV) outcomes trial showed that treatment with Victoza® (liraglutide) resulted in similar reductions in the risk of major cardiovascular events in people with type 2 diabetes at high CV risk, regardless of whether ...
plus
12.06.2017 – 23:16
Novo Nordisk
Tresiba® Demonstrated No Increased Risk Of Major Cardiovascular Events and Significant Reduction in Rates of Severe Hypoglycaemia Compared to Insulin Glargine U100 in the DEVOTE Trial
San Diego (ots/PRNewswire) - Symposium: 3-CT-SY22 Novo Nordisk today announced the primary results from DEVOTE - the first randomised, double-blind, treat-to-target, event-driven trial comparing two basal insulins, Tresiba® (insulin degludec injection 100 U/mL) and insulin glargine U100, in adults with type 2 ...
plus
10.06.2017 – 19:02
Novo Nordisk
Switching to Tresiba® Provides Significant Reductions in Blood Glucose and Lower Rates of Hypoglycaemia in a Real-world Setting
Bagsværd, Denmark (ots/PRNewswire) - Poster Presentations #999-P, #1010-P, #1014-P Findings from the real-world study, EU-TREAT (EUropean TREsiba AudiT), were presented today at the American Diabetes Association's 77th Scientific Sessions (ADA) in San Diego, US. The study showed that people with type 1 diabetes and ...
plus
07.06.2017 – 17:32
Johnson & Johnson Medical GmbH
Johnson & Johnson Medical Devices Launches CareAdvantage, Offering Tailored Support to Help Hospitals and Healthcare Providers in EMEA to Increase Patients' Outcomes and Reduce Costs
Norderstedt, Germany (ots/PRNewswire) - Leveraging 130 years of knowledge and expertise across the Johnson & Johnson Family of Companies, Johnson & Johnson Medical Devices (JJMD) is proud to launch a new approach to help drive value-based healthcare in hospitals across Europe, Middle East and Africa (EMEA) - ...
plus
01.06.2017 – 15:00
Debiopharm International SA
GenePOC announces FDA clearance for revogene(TM) instrument and its GBS LB test
Québec, Canada and Lausanne, Switzerland (ots) - GenePOC announces it received 510(k) clearance from the US Food and Drug Administration to market its first molecular assay to detect Group B Streptococcus and for the revogene molecular diagnostics instrument. GenePOC, Inc. (GenePOC) a member of the Debiopharm Group is pleased to announce that it has received FDA ...
plus
01.06.2017 – 14:02
Royal Philips
Scientific Research Highlights Potential of MR-HIFU Technology for New Cancer Therapies
Amsterdam (ots/PRNewswire) - Proceedings of the National Academy of Science (PNAS) paper* details results of a pre-clinical study into the combined use of drug-loaded temperature sensitive liposomes and MR-HIFU for local tumor treatment. Royal Philips (http://www.philips.com) (NYSE: PHG, AEX: PHIA), a leader in health technology, today announced the publication of a ...
plus
01.06.2017 – 14:00
Debiopharm International SA
Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284
Lausanne, Switzerland (ots) - Debio 1347/CH5183284 was evaluated in patients with FGFR genomically activated advanced solid tumors Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the results from the phase I ...
plus
31.05.2017 – 13:01
Resverlogix Corp.
Resverlogix to Host Epigenetics Focused Symposium at The ERA-EDTA Congress in Madrid, Spain
Calgary, Alberta (ots/PRNewswire) - The symposium titled: "Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?" at the ERA-EDTA Congress highlights BET-inhibition and apabetalone in addressing the significant unmet medical need in chronic kidney disease and cardiovascular disease. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced ...
plus
31.05.2017 – 12:03
Merck Healthcare Germany GmbH
Merck Honors World MS Day by Launching Care Partner Survey with IACO
Darmstadt, Germany (ots/PRNewswire) - - Preliminary research indicates most MS carers are between the ages of 18-34, the prime of their lives - Largest global MS carer survey with International Alliance of Carer Organizations (IACO) to help identify unmet needs and social impact Merck, a leading science and technology company, honors World MS Day 2017 by announcing a ...
plus
30.05.2017 – 13:01
Resverlogix Corp.
Resverlogix Receives Approval From Health Canada to Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
Calgary, Alberta (ots/PRNewswire) - Apabetalone expands in to first orphan disease clinical trial in patients with Fabry disease Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that it has received approval from Health Canada, Therapeutic Products Directorate, to proceed with a clinical ...
plus
24.05.2017 – 15:31
OncoQuest Inc.
OncoQuest to Present Oregovomab Phase II Interim Clinical Results for Front Line Treatment of Ovarian Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
Edmonton, Alberta (ots/PRNewswire) - OncoQuest Inc. ("OncoQuest"), a privately held, biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of cancer, today announced the presentation of initial safety and efficacy data from the company's ...
plus
24.05.2017 – 08:00
Debiopharm International SA
Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen
Lausanne, Switzerland and Waltham, Mass. (ots) - Transaction adds innovative clinical-stage program to expanding Debiopharm portfolio and broadens its clinical development expertise Divestiture aligns with ImmunoGen's focus on strategic growth initiatives and generates near-term value Debiopharm International SA ...
plus
23.05.2017 – 13:01
Resverlogix Corp.
Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success
Calgary, Alberta (ots/PRNewswire) - Nature Reviews Nephrology and Pfizer Inc. discuss BET bromodomain inhibition and apabetalone as viable drug candidates Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today highlighted two additional works involving its lead drug, apabetalone, one recently published ...
plus
22.05.2017 – 08:01
LEO Pharma
Brodalumab, a Novel Biologic for People with Moderate-to-Severe Psoriasis, Receives Positive Opinion from European CHMP
Ballerup, Denmark (ots/PRNewswire) - Opinion from CHMP: "On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product [brodalumab], intended for the treatment of psoriasis[...]The benefits with ...
plus
19.05.2017 – 18:06
LEO Pharma
Brodalumab, a Novel Biologic for People with Moderate-to-Severe Psoriasis, Receives Positive Opinion from European CHMP
Ballerup, Denmark (ots/PRNewswire) - Opinion from CHMP: "On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product [brodalumab], intended for the treatment of psoriasis[...]The benefits with ...
plus
19.05.2017 – 15:09
Merieux Developpement
Mérieux Développement Announces Equity Financing into Xeris Pharmaceuticals
Lyon, France and Boston (ots/PRNewswire) - Mérieux Développement has recently concluded an equity investment into Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on the development and commercialization of novel formulations of injectable drugs. With this additional financing, Xeris Pharmaceuticals expects to fund registration trials and ...
plus
19.05.2017 – 07:01
Shire Pharmaceuticals Group Plc
Shire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology
Zug, Switzerland (ots/PRNewswire) - New clinical and real-life data in chronic hypoparathyroidism, to advance understanding of this rare disease and improve patients' lives Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, announced today new research to be presented on rhPTH(1-84) and on the ...
plus
18.05.2017 – 16:38
National Cancer Centre Singapore (NCCS) and Singapore Clinical Research Institute (SCRI)
American Society of Clinical Oncology (ASCO) Publishes Abstract of SIRveNIB, an Investigator-led Asia Pacific Primary Liver Cancer Study to be Presented at ASCO Annual Meeting in Chicago, 4 June 2017
Singapore (ots/PRNewswire) - The SIRveNIB abstract published on-line in the Journal of Clinical Oncology states that treatment of locally advanced Hepatocellular Carcinoma (HCC) with a single treatment of SIR-Spheres® Y-90 resin microspheres results in Overall Survival not significantly different from twice-daily ...
plus
18.05.2017 – 15:02
Shire Pharmaceuticals Group Plc
The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis
Dublin (ots/PRNewswire) - - Study met primary endpoint demonstrating significantly greater remission rates in patients receiving anti-MAdCAM antibody (SHP647) compared to placebo in three of four tested dose groups - First study to investigate the potential role of anti-MAdCAM antibody in the management of ...
plus
18.05.2017 – 13:01
Shire Pharmaceuticals Group Plc
Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial
Lexington, Massachusetts (ots/PRNewswire) - - Significant reduction in monthly Hereditary Angioedema (HAE) attack rate with infrequent subcutaneous administration - Data to serve as basis for U.S. BLA filing expected in Q4 2017 to Q1 2018 - Shire to host Investor Call today at 10 a.m. ET; details below Shire plc ...
plus
17.05.2017 – 23:02
Merck Healthcare Germany GmbH
Shaping Cancer Care Today and Tomorrow: Merck to Present New Data from Rapidly Evolving Pipeline at ASCO 2017
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or U.S.-based media ASCO Abstract # M7824 (anti-PD-L1/TGF-ß trap): 3006; Avelumab: 9086, 9530, 9557, 4528, 3059, 5037, e21070, e21065, e20581; Tepotinib: 4087, 8547, e15676, 20541; M3814 (DNA-PK): 2556, e14048; M7583 (BTKi): e14101 - ASCO data highlights ...
plus
17.05.2017 – 23:01
Merck Healthcare Germany GmbH
Merck and Pfizer to Present Data Highlighting Potential of Avelumab in Challenging Cancers at ASCO 2017
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - A total of 13 abstracts across seven hard-to-treat cancers highlight the progress of avelumab as a monotherapy and potential novel combination treatment option - New data in metastatic Merkel cell carcinoma and ...
plus

Précédent26272829303132333435Suivant